Ammonium Chloride

Evidence Level: L5

Predicted Indications: 1

Ammonium Chloride

Pharmacist Assessment Report

Ammonium Chloride: From Pharyngitis and Common Cold to Nasal Cavity Disease

One-Sentence Summary

Ammonium chloride is a long-established ingredient in cough and cold preparations, with recorded uses in the knowledge graph for pharyngitis, common cold and nasopharyngitis. The TxGNN model predicts it may be useful for nasal cavity disease, but no clinical trials and no publications currently support this direction, so the prediction rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Pharyngitis, common cold, nasopharyngitis (relations recorded in the knowledge graph; the local licence records contain no indication text)
Predicted New Indication	Nasal cavity disease
TxGNN Prediction Score	0.9994
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Number of approvals	At least 20 licences (the list may be partial)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, ammonium chloride is used in cough and cold syrups, mainly as an expectorant that increases airway secretions. Its recorded uses in upper respiratory conditions (pharyngitis, common cold, nasopharyngitis) are relations from the knowledge graph rather than approved indications.

The upper airway conditions it is linked to sit close to the nasal cavity anatomically and share symptoms such as congestion and mucus. This makes it plausible that the model is picking up on this overlap. However, this is only a hypothesis. “Nasal cavity disease” is also a broad, non-specific category, so it is hard to translate into a defined clinical question. The very high TxGNN score is a computational prediction, not clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

At least 20 single-ingredient licences are valid; the list below shows 5 of them and may be partial. The licence records contain no approved indication text.

Authorization Number	Product Name	Dosage Form	Approved Indication
152200	Nocof Syrup	Syrup, 100 ml bottle	Not stated in the records
249589	Zumcof DX Syrup	Syrup, 100 ml bottle	Not stated in the records
35576	Cofdex Plus Syrup Sweet Orange	Syrup, 100 ml bottle	Not stated in the records
29960	Becodryl Syrup	Syrup, 60 ml bottle	Not stated in the records
193386	Redax Syrup	Syrup, 100 ml bottle	Not stated in the records

Safety Considerations

Contraindications (relations recorded in the knowledge graph, not label text): hypertension and hypertensive disorder, liver failure, impaired renal function, anuria, epilepsy, adrenocortical insufficiency and Addison disease, peptic ulcer disease, hyperthyroidism (Graves disease, thyrotoxicosis), angle-closure glaucoma, ocular hypertension, benign prostatic hyperplasia, bladder neck obstruction, pulmonary edema, myocardial ischemia and coronary artery disease, sudden cardiac arrest, heart conduction disease, anxiety disorder, obsessive-compulsive disorder, insomnia, hypercalcemia, nephrocalcinosis, phosphorus metabolism disease, necrotizing enterocolitis, and others.
Drug Interactions: 21 interactions are recorded.
- Moderate: amphetamine, dextroamphetamine, lisdexamfetamine, metamfetamine, benzphetamine.
- Minor: ephedrine, pseudoephedrine, tricyclic antidepressants (amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine), methadone, mexiletine, flecainide.

Package insert warnings were not available; please refer to the package insert for label safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The only support is a computational score. No trials or publications study nasal cavity disease directly, and the mechanism of action is unavailable, so the evidence level is L5. The condition is also too broad to define a clear clinical question.

To proceed, the following is needed:

Mechanism of action data for ammonium chloride
Package insert warnings and contraindications from the Indian licences
A specific nasal condition (for example, rhinitis or nasal congestion) in place of the broad category, with a targeted literature and trial search
Review of the 21 recorded drug interactions and the knowledge-graph contraindications
Assessment of route and formulation compatibility; all current products are oral syrups or expectorants
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.